$APLM

Apollomics Inc.

Apollomics is a clinical-stage biopharmaceutical company that discovers and develops oncology therapies, particularly for difficult-to-treat and treatment-resistant cancers. Its biomarker-driven approach screens patients for markers that may indicate they could benefit from targeted therapy. Its pipeline includes tumor inhibitors and immuno-oncology candidates, with three product candidates in active clinical-stage development. Vebreltinib, its most advanced candidate, is an oral c-Met inhibitor being studied for cancers with c-Met alterations. Other candidates include the tumor inhibitor APL-102 and the immuno-oncology products APL-501, APL-502 and APL-801. Apollomics conducts clinical development through its global drug development team in the San Francisco Bay Area and a discovery and development team in Hangzhou, China. It works with partners on some candidates, including APL-502, which is developed by CTTQ in China. The company is headquartered in Foster City, California.

No enriched coverage for $APLM in the last 7 days.

No SEC Form 4 filings for $APLM in the last 30 days.

See all $APLM insider activity →
Med

Apollomics GAAP EPS of -$4.04 (NASDAQ:APLM)

Apollomics reported a GAAP EPS of -$4.04 for the first half of 2026, with cash and cash equivalents of $1.0M as of June 30, 2026, according to the company.

Apollomics (NASDAQ: APLM) COO now holds 20,100 shares

Apollomics (APLM) reported that COO Chen Yi-Kuei's 5,000 restricted stock units vested into 5,000 Class A shares on September 15, 2026, increasing his direct holdings to 20,100 shares. He was also granted an option for 8,000 shares at $23.18 each, vesting in 2027. He indirectly holds 121,248 shares through Maxpro Investment Co.

Apollomics CEO Buys Over $7.55 Million In Shares; Shares Rally

Apollomics Inc. (APLM) said CEO Hung-Wen Chen bought shares on Aug. 14, 2026, including 166,667 shares at $12 and 103,333 at $15 directly, plus 266,667 at $15 via King Regent Management. Total buys were about $7.55 million, raising direct holdings to 418,334 and indirect to 1,029,695. APLM shares rose to $23.55 Monday.

APLM sentiment & insider activity

Recent APLM coverage spans insider activity, financial news and earnings.

What's driving APLM

AlphAI scores every news story that mentions APLM with an AI model for sentiment and relevance, and aggregates insider trades from Apollomics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $APLM

Score

Apollomics (NASDAQ: APLM) COO now holds 20,100 shares

Apollomics (APLM) reported that COO Chen Yi-Kuei's 5,000 restricted stock units vested into 5,000 Class A shares on September 15, 2026, increasing his direct holdings to 20,100 shares. He was also granted an option for 8,000 shares at $23.18 each, vesting in 2027. He indirectly holds 121,248 shares through Maxpro Investment Co.

Related tickers